Lomeguatrib

Lomeguatrib

SCHEMBL19549802

Nc1nc(OCc2cc(Br)cs2)c2nc[nH]c2n1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MGMT P16455 17/20 0.67
PIN1 Q13526 2/20 0.40
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CDK1 P06493 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CCNB1 P14635 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CYP2C19 P33261 1/20 0.34
BLM P54132 1/20 0.34
CCNA1 P78396 1/20 0.34
PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lomeguatrib SCHEMBL32671218 1.00 MGMT (0.67) MGMTPIN1LMNACYP1A2CDK1
SCHEMBL28755928 0.85 MGMT (0.49) MGMTPIN1LMNACYP1A2CDK1
SCHEMBL28788534 0.81 MGMT (0.45) MGMTPIN1LMNACYP1A2CDK1
Lomeguatrib SCHEMBL29406067 0.80 MGMT (1.00) MGMTPIN1LMNACYP1A2CDK1
Lomeguatrib SCHEMBL4621691 0.80 MGMT (1.00) MGMTPIN1LMNACYP1A2CDK1
SCHEMBL28756033 0.80 MGMT (0.44) MGMTPIN1LMNACYP1A2CDK1
SCHEMBL28755912 0.78 MGMT (0.43) MGMTPIN1LMNACYP1A2CDK1
SCHEMBL13160258 0.77 MGMT (0.41) MGMTPIN1
SCHEMBL21452794 0.73 PIN1 (0.50) MGMTPIN1LMNACYP1A2CDK1
SCHEMBL8618497 0.72 CDK1 (0.44) MGMTPIN1CDK1CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11992500-B2 Use of methylation inhibitors for the treatment of autoimmune diseases RUSH UNIVERSITY MEDICAL CENTER (US) 2024-05-28 US claimed
US-20210128600-A1 Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases RUSH UNIVERSITY MEDICAL CENTER (US) 2021-05-06 US claimed
US-11992500-B2 Use of methylation inhibitors for the treatment of autoimmune diseases RUSH UNIVERSITY MEDICAL CENTER (US) 2024-05-28 US disclosed
EP-4194548-A1 GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE Janssen Biotech, Inc. (US) 2023-06-14 EP disclosed
US-20210128600-A1 Use of Methylation Inhibitors for the Treatment of Autoimmune Diseases RUSH UNIVERSITY MEDICAL CENTER (US) 2021-05-06 US disclosed
US-20170321285-A1 NLRC5 AS A BIOMARKER FOR CANCER PATIENTS AND A TARGET FOR CANCER THERAPY THE TEXAS A&M UNIVERSITY SYSTEM 2017-11-09 US disclosed